Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair GlobeNewswire - Thu Jan 22, 7:00AM CST

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 36.88 (-2.10%)
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Sun Jan 11, 3:00PM CST

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week...

MBX : 36.88 (-2.10%)
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 GlobeNewswire - Mon Dec 15, 2025

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.88 (-2.10%)
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference GlobeNewswire - Tue Nov 18, 2025

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.88 (-2.10%)
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights GlobeNewswire - Thu Nov 6, 2025

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross...

MBX : 36.88 (-2.10%)
MBX Biosciences to Participate in November Investor Conferences GlobeNewswire - Mon Oct 20, 2025

CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.88 (-2.10%)
MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim Tipranks - Tue Oct 7, 2025

In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on MBX Biosciences, Inc., with a price target of $84.00. The company’s shares closed last Friday at $16.69.Elevate...

MBX : 36.88 (-2.10%)
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum GlobeNewswire - Mon Sep 29, 2025

CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.88 (-2.10%)
MBX Biosciences Announces Pricing of Upsized Public Offering GlobeNewswire - Wed Sep 24, 2025

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.88 (-2.10%)
Close- up of computer chip with AI sign by YAKOBCHUK V via Shutterstock
Stock Indexes Post New Record Highs on AI Optimism Barchart - Mon Sep 22, 2025

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.44%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.55%. December E-mini...

TER : 311.49 (+3.79%)
MSTR : 138.16 (+2.39%)
AMAT : 330.86 (+2.59%)
UAL : 116.46 (+0.47%)
AAPL : 274.62 (-1.17%)
DHI : 153.62 (-1.70%)
SRPT : 18.23 (-1.46%)
HP : 35.75 (-0.61%)
$IUXX : 25,263.47 (+0.75%)
COIN : 167.28 (+1.31%)
ASML : 1,430.42 (+1.23%)
ZNH26 : 112-050 (+0.04%)

Barchart Exclusives

This Analyst Has Finally Had Enough of AI CapEx at Microsoft. Should You Be Done with MSFT Stock Too? Barchart - 2 minutes ago
Microsoft stock is under pressure after a rare analyst downgrade raises uncomfortable questions about whether massive AI spending is finally outpacing near-term returns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot